

Exhibit B

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

UNITED THERAPEUTICS)	
CORPORATION,)	
)	
Plaintiff and Counterclaim-)	
Defendant,)	
)	Civil Action No.
v.)	3:14-cv-5499 (PGD)(LHG)
)	
SANDOZ INC.,)	
)	
Defendant and Counterclaim-)	
Plaintiff.)	

DECLARATION OF CLAYTON H. HEATHCOCK, Ph.D.

I, Clayton H. Heathcock, hereby declare as follows:

1. I have been retained by Sandoz Inc. as an expert in the above captioned matter. I submit this declaration in support of Sandoz's Opening Claim Construction Brief.

2. I have a Ph.D. in Chemistry from the University of Colorado, which I obtained in 1963. I held various professorial ranks in the Department of Chemistry at the University of California at Berkeley from 1964 through 2004. I was Dean of the College of Chemistry from 1999 through 2005 and Chief Scientist of QB3 Berkeley, a branch of the California Institute for Quantitative Bioscience from 2005 to 2008. I am currently Emeritus Professor.

3. For the more than 50 years, I conducted research in organic chemistry. In particular, my work focused on the chemical synthesis of complex, polycyclic natural products.



4. I have published over 280 research papers and book chapters. I have served as Chair of the Division of Organic Chemistry of the American Chemical Society, Chair of the National Institutes of Health Medicinal Chemistry Study Section, Chair of the Gordon Research Conference on Stereochemistry, Chair of the Chemistry Division of the American Association for the Advancement of Science, and Editor-in-Chief of the *Journal of Organic Chemistry* and of the annual publication *Organic Syntheses*. I have received numerous awards and honors for my work in the field of chemistry. Noteworthy examples include the Ernest Guenther Award (ACS) (1986); ACS Award for Creative Work in Organic Synthesis (1990); A.C. Cope Scholar (1990); Prelog Medal, ETH (1991); American Academy of Art and Sciences (1991); National Academy of Sciences (1995); Centenary Medal, Royal Society of Chemistry (1996); H.C. Brown Award (ACS) (2002); Paul Gassman Award for Distinguished Service (ACS) (2004). Additional information regarding my background, experience, and credentials is set forth in my curriculum vitae, which is attached as Exhibit 1 to this declaration.

I. THE '393 PATENT


5. U.S. Patent No. 8,497,393 (“the ’393 patent”) is entitled “Process to prepare treprostinil, the active ingredient in Remodulin®.”¹ I understand that the ’393 patent issued on July 30, 2013 and claims priority to a provisional application filed on December 17, 2007.

6. The ’393 patent has a total of 22 claims. I understand that UTC has asserted six claims in the present litigation: claims 1, 2, 4, 8, 9 and 16.

7. Claim 1 recites as follows:

<p>1. A product comprising a compound of formula I</p>  <p>(I)</p> <p>or a pharmaceutically acceptable salt thereof, wherein said product is prepared by a process comprising</p> <p>(a) alkylating a compound of structure II with an alkylating agent to produce a compound of formula III,</p>  <p>(II)</p>	<p>wherein</p> <p>w=1, 2, or 3;</p> <p>Y₁ is trans-CH=CH—, cis-CH=CH—, —CH₂(CH₂)_m—, or —C=C—; m is 1, 2, or 3;</p> <p>R₇ is</p> <p>(1) —C_pH_{2p}—CH₃, wherein p is an integer from 1 to 5, inclusive,</p> <p>(2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C₁-C₃) alkyl, or (C₁-C₃) alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R₇ is phenoxy or substituted phenoxy, only when R₃ and R₄ are hydrogen or methyl, being the same or different,</p> <p>(3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C₁-C₃)alkyl, or (C₁-C₃)alkoxy, with the proviso that not more than two substituents are other than alkyl,</p> <p>(4) cis-CH=CH—CH₂—CH₃,</p> <p>(5) —(CH₂)₂—CH(OH)—CH₃, or</p> <p>(6) —(CH₂)₃—CH=C(CH₃)₂;</p> <p>—C(L₁)—R₇, taken together is</p> <p>(1) (C₄-C₇)cycloalkyl optionally substituted by 1 to 3 (C₁-C₃) alkyl;</p>
---	---

¹ A copy of the ’393 patent is attached as Exhibit 2 to my Declaration.



8. Claim 1 is drawn to a product comprising a compound of a genus that includes the treprostiniol compound, or a pharmaceutically acceptable salt thereof.

9. Claim 9 is identical to claim 1 except that it is drawn to a product comprising the specific treprostiniol compound, a species of the genus of claim 1, made by the same process.

10. Each of the independent claims 1 and 9 includes limitations that the claimed compound is made by a process comprising three specified steps: (a) alkylating a benzindene triol to form a benzindene nitrile intermediate; (b) hydrolyzing the benzindene nitrile with a base to form treprostiniol acid; and (c) contacting the treprostiniol acid with a base to form treprostiniol salt.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.